Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
Sudeep Tanwar, Freya Rhodes, Ankur Srivastava, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 2, pp. 109-133
Open Access | Times Cited: 183

Showing 1-25 of 183 citing articles:

Role of the Inflammasome in Liver Disease
Marcelle de Carvalho Ribeiro, Gyöngyi Szabó
Annual Review of Pathology Mechanisms of Disease (2021) Vol. 17, Iss. 1, pp. 345-365
Open Access | Times Cited: 176
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 161
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 46-56
Closed Access | Times Cited: 91
Periodontitis, chronic liver diseases, and the emerging oral‐gut‐liver axis
Emmanuel Albuquerque‐Souza, Sinem E. Sahingur
Periodontology 2000 (2022) Vol. 89, Iss. 1, pp. 125-141
Open Access | Times Cited: 73
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
Hafiza Madiha Jaffar, Fahad Al‐Asmari, Faima Atta Khan, et al.
Food Science & Nutrition (2024) Vol. 12, Iss. 5, pp. 3097-3111
Open Access | Times Cited: 18
The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
Emad Shamsan, Maged Almezgagi, Mohammed Gamah, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 17
Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Arshi Khanam, Paul Saleeb, Shyam Kottilil
Cells (2021) Vol. 10, Iss. 5, pp. 1097-1097
Open Access | Times Cited: 81
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 799-815
Closed Access | Times Cited: 53
COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR
Chen-Yu Zhang, Xiaohua Tan, Hui‐Hui Yang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8267-8267
Open Access | Times Cited: 43
Non-alcoholic fatty liver disease combined with rheumatoid arthritis exacerbates liver fibrosis by stimulating co-localization of PTRF and TLR4 in rats
Shengpeng Zhang, Peng Zhu, Jianan Yuan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 27
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells
Li Gu, Yahui Zhu, Maiya Lee, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 19
Open Access | Times Cited: 23
Advances in pathogenesis of preeclampsia
Mei Yang, Menghui Wang, Nanfang Li
Archives of Gynecology and Obstetrics (2024) Vol. 309, Iss. 5, pp. 1815-1823
Closed Access | Times Cited: 14
SIRT3: A potential therapeutic target for liver fibrosis
Yan Ning, Xinyue Dou, Zhichao Wang, et al.
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108639-108639
Closed Access | Times Cited: 8
The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
Paulina Vidal‐Cevallos, Adriana P. Sorroza-Martínez, Norberto C. Chávez‐Tapia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4397-4397
Open Access | Times Cited: 8
Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases
Xiaolin Xiao, Qichao Hu, Xinyu Deng, et al.
Pharmacological Research (2021) Vol. 175, pp. 106005-106005
Closed Access | Times Cited: 49
Regulatory mechanism of HIF-1α and its role in liver diseases: a narrative review
Qingfei Chu, Xinyu Gu, Qiuxian Zheng, et al.
Annals of Translational Medicine (2021) Vol. 10, Iss. 2, pp. 109-109
Open Access | Times Cited: 46
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Anshika Jangra, Ashish Kothari, Phulen Sarma, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1500-1500
Open Access | Times Cited: 31
Role of Exosomes in Chronic Liver Disease Development and Their Potential Clinical Applications
Chen Wang, Jinwen Liu, Yongmin Yan, et al.
Journal of Immunology Research (2022) Vol. 2022, pp. 1-15
Open Access | Times Cited: 27
MANF brakes TLR4 signaling by competitively binding S100A8 with S100A9 to regulate macrophage phenotypes in hepatic fibrosis
Chao Hou, Dong Wang, Mingxia Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4234-4252
Open Access | Times Cited: 21
NLRP3 inflammasome in hepatic diseases: A pharmacological target
Erika Ramos‐Tovar, Pablo Muriel
Biochemical Pharmacology (2023) Vol. 217, pp. 115861-115861
Closed Access | Times Cited: 20
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17514-17514
Open Access | Times Cited: 20
Rubicon siRNA-encapsulated liver-targeting nanoliposome is a promising therapeutic for non-alcoholic fatty liver disease
Yuting Zhang, Hanqi Wang, Caili Xu, et al.
International Journal of Pharmaceutics (2025), pp. 125291-125291
Closed Access
Impact of Mlkl or Ripk3 deletion on age-associated liver inflammation, metabolic health, and lifespan
Sabira Mohammed, Phoebe Ohene-Marfo, Chao Jiang, et al.
GeroScience (2025)
Open Access
Phloretin mitigates oxidative injury, inflammation, and fibrogenic responses via restoration of autophagic flux in in vitro and preclinical models of NAFLD
Jyoti Chhimwal, Abhishek Goel, Mahesh Sukapaka, et al.
The Journal of Nutritional Biochemistry (2022) Vol. 107, pp. 109062-109062
Closed Access | Times Cited: 24
When healing turns into killing – the pathophysiology of pancreatic and hepatic fibrosis
Paweł E. Ferdek, Daria Krzysztofik, Kinga B. Stopa, et al.
The Journal of Physiology (2022) Vol. 600, Iss. 11, pp. 2579-2612
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top